CNW | CannTrust and Australia’s Gold Coast University Hospital …

The six-month study will be led by Gold Coast Neurologist, Dr. Arman Sabet, MD. Gold Coast is one of Australia’s leading tertiary referral institutions for ALS management and Dr. Sabet has been involved in many international clinical trials specializing in neuromuscular disorders and stroke.

Dr. Sabet’s research will also analyze the effects of CannTrust CBD oil capsules on study participants’ spasticity, pain, weight loss and quality of life.

“ALS is a fatal disease with no known cure. This study will help advance our understanding of the potential effects of CannTrust’s standardized CBD oil capsules on ALS/MND, both as a disease modifying agent and as a symptomatic treatment and will become the basis for conducting future cannabinoid and ALS clinical trials,” said Dr. Sabet, MD, Senior Staff Specialist, Gold Coast University Hospital.

“The rate of ALS progression is often rapid, creating high levels of disability for patients. People diagnosed with ALS

... read more at: https://www.newswire.ca/news-releases/canntrust-and-australias-gold-coast-university-hospital-partner-in-als-clinical-trial-687870271.html